Observational Study “Aubagio”

Observed Drugs

Title of the Observational Study

PASS: HMR1726-OBS12751: An International Pregnancy Exposure registry of Women With Multiple Sclerosis (MS) exposed to Teriflunomide

Registered on
Start date
End date
Executing company
INC Research GmbH
Genzyme (Sanofi-Aventis groupe for Europe)
Number of Docs1
Number of Patients2
Payment per Patient3
8427.52 €
Fee details
Registration (early in pregnancy): € 2106,88, Mid-Pregnancy Follow-up (20 weeks): € 2106,88, Pregnancy Outcome (40 weeks): € 2106,88, Infant Follow-up (1 year): € 842,75, Targeted Follow-up: € 1264,13


Independent journalism needs independent funding

Others can write stories. We want to reveal. We are the first investigative newsroom in Germany, which is independent, ad-free, and non-profit.

For us, the core of journalism means uncovering injustice and shortcomings in society. That’s why we investigate corruption in the health system, politicians abusing their power, and an elite that believes that rules are for the others.

To do our job, we need people, who support us. We ask you, too, to become a member and enable the work of 16 investigative journalists at CORRECTIV.

We are convinced that without independent and critical media, democracy fought for and won by our ancestors, cannot survive for long.